Last reviewed · How we verify
NCT06112782
Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality
NA trial testing Keravive by Hydrafacial Treatments in Androgenic Alopecia in 44 participants. Completed in 31 January 2020.
31 January 2020
Quick facts
| Lead sponsor | Beauty Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 44 |
| Start date | 1 July 2019 |
| Primary completion | 31 January 2020 |
| Estimated completion | 31 January 2020 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Keravive by Hydrafacial Treatments
Conditions studied
- Androgenic Alopecia — all drugs for Androgenic Alopecia →
Sponsor
Beauty Health
Who can join
Adults 30 to 55, any sex, with Androgenic Alopecia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aims to assess the efficacy and safety of Keravive by Hydrafacial treatments and Keravive Peptide Spray for scalp health and enhancing hair quality in patients with androgenic alopecia. This study is intended to be a single arm study. Suitable subjects who meet all inclusion criteria and consented will undergo 3 in-office Keravive by Hydrafacial treatments at Day 0 and Weeks 4 and 8 in combination with daily application on Keravive Peptide Spray at home. Subjects will be assessed at Day 0, and Weeks 4, 8, and 20 by investigators using the Norwood Scale (males), Ludwig Classification (females), and a series of Likert scales for ranking improvement in scalp health and hair quality.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06112782
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Androgenic Alopecia
Currently open trials in the same condition.
- NCT07373054 — Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic Alopecia · NA · recruiting
- NCT07107841 — Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site) · NA · recruiting
- NCT07203599 — A Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes · Phase 1, PHASE2 · recruiting
- NCT06697080 — Umbilical Cord-derived Mesenchymal Stem Cell Exosomes on Hair Growth in Patients With Androgenetic Alopecia · NA · active not recruiting
- NCT05938569 — Computer-Assisted Hair Restoration Study Using ARTAS System · NA · recruiting
Other Beauty Health trials
Trials by the same sponsor.
- NCT06032286 — Evaluation of Efficacy and Safety of the Skinstylus Sterilock Microneedling System for the Treatment of Facial Wrinkles · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06112782 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beauty Health
- Last refreshed: 1 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06112782.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing